Patents by Inventor B. Kenneth Koe

B. Kenneth Koe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of treating chemical dependencies using sertraline
    Patent number: 5130338
    Abstract: A method of treating a chemical dependency in a mammal, comprising administering to a mammal in need of such treatment an amount of the compound (1S-cis)-4-(3, 4-dichlorophenyl)-1,2,3,4-tetraahydro-N-methyl-1-naphthalenamine, also known by the generic name sertraline, or a pharmaceutically acceptable salt thereof, effective in reducing or alleviating such dependency.
    Type: Grant
    Filed: February 28, 1991
    Date of Patent: July 14, 1992
    Assignee: Pfizer Inc.
    Inventors: Nicholas G. Bacopoulos, Peter A. Blick, B. Kenneth Koe, Evan R. Norris
  • Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of inflammation and as immunosuppressants
    Patent number: 5061728
    Abstract: 4-Phenyl-1,2,3,4-tetrahydro-1-napthalenamine derivatives have been found useful for the treatment of psychosis, inflammation and as immunosuppressants.
    Type: Grant
    Filed: December 5, 1990
    Date of Patent: October 29, 1991
    Assignee: Pfizer Inc.
    Inventor: B. Kenneth Koe
  • Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
    Patent number: 4981870
    Abstract: 4-Phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives have been found useful for the treatment of psychosis, inflammation and as immunosuppressants.
    Type: Grant
    Filed: March 7, 1989
    Date of Patent: January 1, 1991
    Assignee: Pfizer Inc.
    Inventor: B. Kenneth Koe
  • Antidepressant derivatives of trans-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
    Patent number: 4556676
    Abstract: Novel trans-isomeric derivatives of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine are useful as antidepressant agents. These novel compounds act to block the synaptosomal uptake of norepinephrine and serotonin (5-hydroxy-tryptamine), thereby alleviating abnormalities at central receptor sites. The preferred embodiment is the enantiomer trans-(1R)-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalen amine and its pharmaceutically acceptable acid addition salts.
    Type: Grant
    Filed: September 5, 1980
    Date of Patent: December 3, 1985
    Assignee: Pfizer Inc.
    Inventors: Willard M. Welch, Jr., Charles A. Harbert, B. Kenneth Koe, Allen R. Kraska
  • Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
    Patent number: 4536518
    Abstract: Novel cis-isomeric derivatives of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine are useful as antidepressant agents. These novel compounds act to block the synaptosomal uptake of serotonin (5-hydroxy-tryptamine), thereby alleviating serotonin abnormalities at central receptor sites. The preferred embodiment is the enantiomer cis-(1S)-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenam ine and its pharmaceutically acceptable acid addition salts.
    Type: Grant
    Filed: November 1, 1979
    Date of Patent: August 20, 1985
    Assignee: Pfizer Inc.
    Inventors: Willard M. Welch, Jr., Charles A. Harbert, B. Kenneth Koe, Allen R. Kraska